Literature DB >> 9852972

Varicella-zoster virus IE63, a virion component expressed during latency and acute infection, elicits humoral and cellular immunity.

C Sadzot-Delvaux1, A M Arvin, B Rentier.   

Abstract

Varicella-zoster virus (VZV) latency in human dorsal root ganglia is characterized by the transcription of large regions of its genome and by the expression of large amounts of some polypeptides, which are also expressed during lytic cycles. The immediate early 63 protein (IE63) is a virion component expressed very early in cutaneous lesions and the first viral protein detected during latency. Immune response against IE63 has been evaluated among naturally immune adults with a history of chickenpox: Specific antibodies were detected in serum, and most subjects who had a T cell proliferation with unfractionated VZV antigens had T cell recognition of purified IE63. The cytotoxic T cell (CTL) response to IE63 was equivalent to CTL recognition of IE62, the major tegument component of VZV, whose immunogenicity has been previously described. T cell recognition of IE63 and other VZV proteins is one of the likely mechanisms involved in controlling VZV reactivation from latency.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9852972     DOI: 10.1086/514259

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  Varicella-zoster virus glycoproteins B and E are major targets of CD4+ and CD8+ T cells reconstituting during zoster after allogeneic transplantation.

Authors:  Patrick Kleemann; Eva Distler; Eva M Wagner; Simone Thomas; Sebastian Klobuch; Steffi Aue; Elke Schnürer; Hansjörg Schild; Matthias Theobald; Bodo Plachter; Stefan Tenzer; Ralf G Meyer; Wolfgang Herr
Journal:  Haematologica       Date:  2011-12-29       Impact factor: 9.941

2.  Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus.

Authors:  J G Smith; X Liu; R M Kaufhold; J Clair; M J Caulfield
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

Review 3.  A comparison of herpes simplex virus type 1 and varicella-zoster virus latency and reactivation.

Authors:  Peter G E Kennedy; Joel Rovnak; Hussain Badani; Randall J Cohrs
Journal:  J Gen Virol       Date:  2015-03-20       Impact factor: 3.891

4.  Construction of recombinant mouse IgG1 antibody directed against varicella zoster virus immediate early protein 63.

Authors:  Niklaus H Mueller; Laurie L Graf; Andrew J Shearer; Gregory P Owens; Donald H Gilden; Randall J Cohrs
Journal:  Hybridoma (Larchmt)       Date:  2008-02

Review 5.  T-cell immunity to human alphaherpesviruses.

Authors:  Werner J D Ouwendijk; Kerry J Laing; Georges M G M Verjans; David M Koelle
Journal:  Curr Opin Virol       Date:  2013-05-08       Impact factor: 7.090

6.  Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells.

Authors:  Miyuki Tanaka; Haruko Tashiro; Bilal Omer; Natasha Lapteva; Jun Ando; Minhtran Ngo; Birju Mehta; Gianpietro Dotti; Paul R Kinchington; Ann M Leen; Claudia Rossig; Cliona M Rooney
Journal:  Clin Cancer Res       Date:  2017-02-09       Impact factor: 12.531

7.  Zoster Vaccination Increases the Breadth of CD4+ T Cells Responsive to Varicella Zoster Virus.

Authors:  Kerry J Laing; Ronnie M Russell; Lichun Dong; D Scott Schmid; Michael Stern; Amalia Magaret; Jürgen G Haas; Christine Johnston; Anna Wald; David M Koelle
Journal:  J Infect Dis       Date:  2015-03-17       Impact factor: 5.226

8.  Herpes simplex virus and varicella zoster virus, the house guests who never leave.

Authors:  Paul R Kinchington; Anthony J St Leger; Jean-Marc G Guedon; Robert L Hendricks
Journal:  Herpesviridae       Date:  2012-06-12

9.  Varicella zoster-specific CD4+Foxp3+ T cells accumulate after cutaneous antigen challenge in humans.

Authors:  Milica Vukmanovic-Stejic; Daisy Sandhu; Toni O Sobande; Elaine Agius; Katie E Lacy; Natalie Riddell; Sandra Montez; One B Dintwe; Thomas J Scriba; Judith Breuer; Janko Nikolich-Zugich; Graham Ogg; Malcolm H A Rustin; Arne N Akbar
Journal:  J Immunol       Date:  2013-01-02       Impact factor: 5.422

10.  Effector and Central Memory Poly-Functional CD4(+) and CD8(+) T Cells are Boosted upon ZOSTAVAX(®) Vaccination.

Authors:  Janet J Sei; Kara S Cox; Sheri A Dubey; Joseph M Antonello; David L Krah; Danilo R Casimiro; Kalpit A Vora
Journal:  Front Immunol       Date:  2015-10-29       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.